Add BrightSurf on Google Email

Defusing a ‘ticking time bomb’: Groundbreaking research offers early clues to stomach cancer development

Researchers identified 26 'driver genes' that play a pivotal role in the transition to stomach cancer, providing a critical window for early detection and targeted prevention. The study's findings offer new insights into the mechanisms governing the transformation of intestinal metaplasia into stomach cancer.

SourceDuke-NUS Medical School·JournalCancer Cell·TypeExperimental study·DateDec 11, 2023

Two drugs reverse key pancreatic cancer step in the lab

Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.

SourceUniversity of Florida·JournalCell Death Discovery·TypeExperimental study·DateOct 19, 2022

New studies add to understanding of treatments for Barrett's esophagus

Two new studies evaluate the safety and effectiveness of endoscopic submucosal dissection (ESD) and liquid nitrogen spray cryotherapy (LNSCT) in treating Barrett's esophagus. ESD was found to have high en-bloc and curative resection rates, while LNSCT showed long-term efficacy in eliminating dysplasia and intestinal metaplasia.

SourceAmerican Society for Gastrointestinal Endoscopy·JournalGastrointestinal Endoscopy·DateOct 6, 2017

Radiofrequency ablation effectively treats Barrett's esophagus

A systematic review and meta-analysis found that radiofrequency ablation is a safe and effective treatment for most patients with dysplastic Barrett's esophagus. The procedure led to complete eradication of dysplasia in 91% of patients, while intestinal metaplasia was eradicated in 78%, and recurrent metaplasia occurred in 13%.

SourceAmerican Gastroenterological Association·JournalClinical Gastroenterology and Hepatology·DateOct 2, 2013

Study shows long-term success rates for eradication of Barrett's esophagus after endoluminal therapies

A study from researchers at the Hospital of the University of Pennsylvania reports that endoluminal therapies combining resection and ablation techniques have a high success rate in eradicating Barrett's esophagus, with durable results. Persistent vigilant surveillance is required due to recurrence risks.

SourceAmerican Society for Gastrointestinal Endoscopy·JournalGastrointestinal Endoscopy·DateFeb 12, 2013

Factors increasing the risk of atrophic gastritis and intestinal metaplasia

Research found that IL-8 and MIF gene polymorphisms significantly increased the risk of severe atrophic gastritis and intestinal metaplasia, particularly when H. pylori infection was present. This study provides a basis for therapeutic decisions, such as H. pylori eradication therapy, to prevent gastric cancer progression.

SourceWorld Journal of Gastroenterology·JournalWorld Journal of Gastroenterology·DateApr 12, 2010

Landmark UNC-led study finds radiofrequency ablation is effective treatment for Barrett's esophagus

A landmark UNC-led study finds radiofrequency ablation significantly effective in treating dysplasia in people with Barrett's esophagus, eradicating abnormal cells and reducing cancer risk. The procedure showed high rates of complete eradication of intestinal metaplasia and progression to disease.

SourceUniversity of North Carolina Health Care·JournalNew England Journal of Medicine·DateMay 27, 2009